Eliptica today announced that it has completed the measurement of 50,000 plasma proteomes from UK Biobank, a major milestone in the company’s mission to translate population-scale blood proteomics into future tests for earlier disease detection.

The dataset represents one of the largest mass-spectrometry-based plasma proteomics efforts of its kind. By linking deep molecular measurements from blood with longitudinal health data, Eliptica aims to identify early disease-associated signals that may support future blood-based tests for earlier detection, risk stratification, monitoring and prevention.

Eliptica’s platform combines high-throughput plasma proteomics, advanced mass spectrometry and AI models designed to learn reusable representations of human plasma biology. The completion of this milestone provides a foundation for discovering molecular patterns associated with future disease outcomes across large, diverse populations.

“Measuring 50,000 UK Biobank proteomes is a major technical and scientific milestone for Eliptica,” said Charles Brigden, CEO of Eliptica. “Population-scale proteomics gives us the opportunity to move beyond narrow biomarker panels and towards a deeper molecular view of human health.”

“This milestone gives Eliptica the scale needed to study human disease biology directly in blood,” said Markus Ralser, CSO and scientific co-founder of Eliptica. “Population-scale plasma proteomics can reveal molecular patterns that are difficult to detect in smaller studies and may become the basis for future early-detection tests.”

The milestone also strengthens Eliptica’s work towards building AI models of the human plasma proteome. These models are designed to learn from billions of mass-spectrometry signals and identify disease-associated patterns that may not be visible in smaller studies.

“Our aim is to turn population-scale plasma proteomics into clinically useful disease insight,” said Aleksej Zelezniak, CTO and scientific co-founder of Eliptica. “This milestone gives us the scale needed to develop more robust models of blood-based human biology and prioritise signatures for future diagnostic testing.”

Eliptica will use the dataset to support discovery and validation of proteomic signatures linked to early disease biology, with a focus on future clinical applications in earlier detection, risk stratification and preventive health.

About Eliptica

Eliptica is a London-based precision-health company building population-scale plasma proteomics and AI models for earlier disease detection. The company combines mass spectrometry, longitudinal human health data and machine learning to discover blood-based molecular signatures that may support future clinical testing.

Media contact

Eliptica
Email: info@eliptica.bio
Website: https://www.eliptica.bio

About UK Biobank

UK Biobank is the world’s most comprehensive source of biomedical data available for health research in the public interest. Over the past 15 years we have collected biological, health and lifestyle information from 500,000 UK volunteers. The dataset is continuously growing, with additions including the world’s largest set of whole genome sequencing data, imaging data from 100,000 participants and a first-of-its kind set of protein biomarkers from 54,000 participants. Since 2012, scientists from universities, charities, companies and governments across the world can apply to use the data to advance modern medicine and drive the discovery of new preventions, treatments and cures. Over 22,000 researchers, based in more than 60 countries, are using UK Biobank data, and more than 18,000 peer-reviewed scientific papers have been published as a result. The data are de-identified and stored on our secure cloud-based platform. UK Biobank is a registered charity and was established by Wellcome and the Medical Research Council in 2003. You can read more about our funding here.